Abstract
Introduction
Insulin prescribing practices and physician perception of unmet needs vary widely among the seven major markets. Datamonitor surveyed 199 primary care physicians and specialists across these markets on their type 2 diabetes treatment choices and prescribing behavior.
Features and benefits
• Analyze country-specific physician insulin use by therapy line and insulin class.
• Compare physician-reported trends in insulin use by class.
• Use key opinion leader insight to explain reported trends and unmet needs in the insulin market.
• Identify opportunities for insulin and non-insulin therapies to target underserved markets and physician cohorts.
Highlights
Physicians report using insulin therapy in over one-third of patients in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). Insulins are predominantly used at third-line therapy and later, and as part of combination treatment regimes. Physicians expect their use of insulin to increase in the future.
Insulin use varies significantly between markets, from a low of 22% patient share in France and the UK, where oral drugs are preferred, to 43% of patients at using insulin at the current time, in Germany. Markets with higher use also have earlier initiation of insulin.
Basal insulins and prandial insulin, particularly the analogs, have come to dominate insulin therapy in recent times. Lantus dominates basal insulin use, on the basis of its concentration profile in the body. However, little difference is perceived between the insulin options, and individual patient response is a major factor.
Your key questions answered
• Delve into primary data from 199 seven major market physicians on present insulin usage and trends.
• Use key opinion leader insight to elucidate differences in prescribing practices among the major markets.
• Identify unmet needs in insulin therapy and opportunities in the type 2 diabetes treatment algorithm.
Table of Contents
Executive Summary
Strategic scoping and focus
Datamonitor key findings
Diabetes reports in the seven major markets
Published diabetes reports
OVERVIEW
Catalyst
Summary
METHODOLOGY
Insulins in the treatment algorithm
Benefits and shortcomings of this survey method
INSULINS IN THE TYPE 2 DIABETES TREATMENT ALGORITHM
Overall insulin use
Insulin market share varies widely in different markets
Insulins used mainly as later-line therapy
Insulin use by class
Class comparison: basal insulins take major share of insulin-treated patients
Basal insulins
Prandial insulins
Intermediate-acting insulins
Premixed insulins
Brand share in key classes
Basal insulin use by brand
Prandial insulin use by brand
INSULIN PRESCRIBING PRACTICES AND UNMET NEEDS
Trends in insulin use
Insulin use is growing across the seven major markets
Analog insulin use grows at the expense of older classes
Initiation of insulin therapy
Indications for insulin use in type 2 diabetes
Insulin and other drugs: physicians see metformin as leading combination option
Time to initiation of insulin therapy
HbA1c and insulin treatment
Referral to a specialist
Patient compliance with insulin treatment
Unmet needs in insulin therapy
Conclusions
BIBLIOGRAPHY
Journal papers
Online sources
APPENDIX
Datamonitor’s type 2 diabetes physician survey
Contributing experts
Report methodology
